异动解读 | 伊克力西斯发布季度财报后盘中大涨5.05%，超出市场预期

异动解读

Aug 02, 2025

今日盘中，生物制药公司伊克力西斯（EXEL）股价大涨5.05%，引起市场广泛关注。这一涨势与公司刚刚发布的2025财年第二季度财报密切相关。

根据财报显示，伊克力西斯第二季度净利润为1.85亿美元，同比下降18.14%；营业收入为5.68亿美元，同比下降10.83%；每股基本收益为0.68美元。尽管年度比较数据出现下滑，但这些结果似乎超出了市场预期，推动了股价的上涨。公司稳健的财务状况也可能增强了投资者信心，报告期内公司总负债为6.45亿美元，无短期债务，资产负债比为4.16，流动比率为3.52，显示出良好的偿债能力和流动性。

值得注意的是，截至8月2日，有19家机构对伊克力西斯给出了目标价预测。平均目标价为45.11美元，最低36.00美元，最高60.00美元。这些评级可能进一步支撑了投资者对公司未来发展的积极预期。作为一家专注于癌症治疗的生物制药公司，伊克力西斯的核心产品包括用于治疗多种癌症的cabozantinib（商品名Cometriq和Cabometyx）以及与罗氏合作开发的用于治疗黑色素瘤的Cotellic。公司在肿瘤学领域的持续创新和市场表现，可能是投资者看好其长期发展前景的重要因素。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1127801763"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127801763\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127801763?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-02 02:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127801763","market":"us","top_or_hot":-1,"title":"异动解读 | 伊克力西斯发布季度财报后盘中大涨5.05%，超出市场预期","media":"异动解读","content":"<p>今日盘中，生物制药公司伊克力西斯（EXEL）股价大涨5.05%，引起市场广泛关注。这一涨势与公司刚刚发布的2025财年第二季度财报密切相关。</p>\n\n<p>根据财报显示，伊克力西斯第二季度净利润为1.85亿美元，同比下降18.14%；营业收入为5.68亿美元，同比下降10.83%；每股基本收益为0.68美元。尽管年度比较数据出现下滑，但这些结果似乎超出了市场预期，推动了股价的上涨。公司稳健的财务状况也可能增强了投资者信心，报告期内公司总负债为6.45亿美元，无短期债务，资产负债比为4.16，流动比率为3.52，显示出良好的偿债能力和流动性。</p>\n\n<p>值得注意的是，截至8月2日，有19家机构对伊克力西斯给出了目标价预测。平均目标价为45.11美元，最低36.00美元，最高60.00美元。这些评级可能进一步支撑了投资者对公司未来发展的积极预期。作为一家专注于癌症治疗的生物制药公司，伊克力西斯的核心产品包括用于治疗多种癌症的cabozantinib（商品名Cometriq和Cabometyx）以及与罗氏合作开发的用于治疗黑色素瘤的Cotellic。公司在肿瘤学领域的持续创新和市场表现，可能是投资者看好其长期发展前景的重要因素。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 伊克力西斯发布季度财报后盘中大涨5.05%，超出市场预期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 伊克力西斯发布季度财报后盘中大涨5.05%，超出市场预期\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-08-02 02:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>今日盘中，生物制药公司伊克力西斯（EXEL）股价大涨5.05%，引起市场广泛关注。这一涨势与公司刚刚发布的2025财年第二季度财报密切相关。</p>\n\n<p>根据财报显示，伊克力西斯第二季度净利润为1.85亿美元，同比下降18.14%；营业收入为5.68亿美元，同比下降10.83%；每股基本收益为0.68美元。尽管年度比较数据出现下滑，但这些结果似乎超出了市场预期，推动了股价的上涨。公司稳健的财务状况也可能增强了投资者信心，报告期内公司总负债为6.45亿美元，无短期债务，资产负债比为4.16，流动比率为3.52，显示出良好的偿债能力和流动性。</p>\n\n<p>值得注意的是，截至8月2日，有19家机构对伊克力西斯给出了目标价预测。平均目标价为45.11美元，最低36.00美元，最高60.00美元。这些评级可能进一步支撑了投资者对公司未来发展的积极预期。作为一家专注于癌症治疗的生物制药公司，伊克力西斯的核心产品包括用于治疗多种癌症的cabozantinib（商品名Cometriq和Cabometyx）以及与罗氏合作开发的用于治疗黑色素瘤的Cotellic。公司在肿瘤学领域的持续创新和市场表现，可能是投资者看好其长期发展前景的重要因素。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXEL","symbol_name":"伊克力西斯","start_time":0,"source_url":"","article_id":"1127801763","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127801763","pubTimestamp":1754072700,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"今日盘中，生物制药公司伊克力西斯股价大涨5.05%，引起市场广泛关注。这一涨势与公司刚刚发布的2025财年第二季度财报密切相关。根据财报显示，伊克力西斯第二季度净利润为1.85亿美元，同比下降18.14%；营业收入为5.68亿美元，同比下降10.83%；每股基本收益为0.68美元。值得注意的是，截至8月2日，有19家机构对伊克力西斯给出了目标价预测。平均目标价为45.11美元，最低36.00美元，最高60.00美元。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"EXEL":"伊克力西斯"},"translate_title":"Interpretation of changes | Iclexis rose 5.05% in intraday trading after releasing its quarterly financial report, exceeding market expectations","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXEL":1},"content_text":"今日盘中，生物制药公司伊克力西斯（EXEL）股价大涨5.05%，引起市场广泛关注。这一涨势与公司刚刚发布的2025财年第二季度财报密切相关。\n根据财报显示，伊克力西斯第二季度净利润为1.85亿美元，同比下降18.14%；营业收入为5.68亿美元，同比下降10.83%；每股基本收益为0.68美元。尽管年度比较数据出现下滑，但这些结果似乎超出了市场预期，推动了股价的上涨。公司稳健的财务状况也可能增强了投资者信心，报告期内公司总负债为6.45亿美元，无短期债务，资产负债比为4.16，流动比率为3.52，显示出良好的偿债能力和流动性。\n值得注意的是，截至8月2日，有19家机构对伊克力西斯给出了目标价预测。平均目标价为45.11美元，最低36.00美元，最高60.00美元。这些评级可能进一步支撑了投资者对公司未来发展的积极预期。作为一家专注于癌症治疗的生物制药公司，伊克力西斯的核心产品包括用于治疗多种癌症的cabozantinib（商品名Cometriq和Cabometyx）以及与罗氏合作开发的用于治疗黑色素瘤的Cotellic。公司在肿瘤学领域的持续创新和市场表现，可能是投资者看好其长期发展前景的重要因素。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}